Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1270-1276

  Ladetto, Marco ^a   Magni, Michele ^b   Pagliano, Gloria ^a   De Marco, Federica ^a   Drandi, Daniela ^a   Ricca, Irene ^a   Astolfi, Monica ^a   Matteucci, Paola ^a   Guidetti, Anna ^a   Mantoan, Barbara ^a   Bodoni, Chiara Lobetti ^a   Zanni, Manuela ^a   Boccadoro, Mario ^a   Gianni, Alessandro M ^b,c   Tarella, Corrado ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Maintenance therapy; Mantle cell lymphoma; Minimal residual disease; Molecular remission; Monoclonal antibodies

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; DNA SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; FOLLOW UP; GENE REARRANGEMENT; HUMAN; INFECTION; MAINTENANCE THERAPY; MALE; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG EVALUATION; FOLLOW-UP STUDIES; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, MANTLE-CELL; MALE; MELPHALAN; MIDDLE AGED; MITOXANTRONE; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; PREDNISONE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 33845249942     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.07.007     Document Type: Article

References (26)

1. Lenz G., Dreyling M., and Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 83 (2004) 71-77
2. Andersen N.S., Donovan J.W., Borus J.S., et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 90 (1997) 4212-4221
3. Freedman A.S., Neuberg D., Gribben J.G., et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 16 (1998) 13-18
4. Corradini P., Astolfi M., Cherasco C., et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 89 (1997) 724-731
5. Ganti A.K., Bierman P.J., Lynch J.C., Bociek R.G., Vose J.M., and Armitage J.O. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 16 (2005) 618-624
6. Witzig T.E. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23 (2005) 6409-6414
7. Brugger W. Clearing minimal residual disease with rituximab consolidation therapy. Semin Oncol 31 suppl 2 (2004) 33-37
8. Foran J.M., Rohatiner Ama Z.S., Cunningham D., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18 (2000) 317-324
9. Ghielmini M., Schmitz S.F., Burki K., et al., Swiss Group for Clinical Cancer Research (SAKK). The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann Oncol 11 suppl 1 (2000) 123-126
10. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23 (2005) 1984-1992
11. Magni M., Di Nicola M., Devizzi L., et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 96 (2000) 864-869
12. Gianni A.M., Magni M., Martelli M., et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102 (2003) 749-755
13. Pott C., Schrader C., Gesk S., et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107 (2006) 2271-2278
14. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17 (1999) 1244-1253
15. Olsson K., Gerard C.J., Zehnder J., et al. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD). Leukemia 13 (1999) 1833-1842
16. Ladetto M., Donovan J.W., Harig S., et al. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 6 (2000) 241-253
17. Donovan J.W., Ladetto M., Zou G., et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 95 (2000) 2651-2658
18. Voena C., Ladetto M., Astolfi M., et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11 (1997) 1793-1798
19. Gribben J.G., Neuberg D., Freedman A.S., et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81 (1993) 3449-3457
20. Corradini P., Ladetto M., Astolfi M., et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br J Haematol 94 (1996) 376-378
21. Hainsworth J.D., Litchy S., Shaffer D.W., Lackey V.L., Grimaldi M., and Greco F.A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23 (2005) 1088-1095
22. Hochster H.S., Weller E., Gascoyne R.D., et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106 (2005) 349
23. Van Oers M.H.J., Van Glabbeke M., Teodorovic I., et al. Chimeric Anti-CD20 monoclonal antibody (rituximab; mabthera) in remission induction and maintenance treatment of relapsed /resistant Follicular Non-Hodgkin's lymphoma: final analysis of a phase III randomized intergroup clinical trial. Blood 106 (2005) 353
24. Ghielmini M., Schmitz S.F.H., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23 (2005) 705-711
25. Paschka P., Merx K., and Hochhaus A. Molecular surveillance of chronic myeloid leukemia patients in the imatinib era-evaluation of response and resistance. Acta Haematol 112 (2004) 85-92
26. Lo Coco F., Breccia M., Noguera N., and Miller Jr. W.H. Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia. Best Pract Res Clin Haematol 16 (2003) 653-670